Antibe Reports Q3 2023 Interim Financial and Operating Results
– Recent animal data on otenaproxesul’s new formulation confirm rapid drug uptake and potential for effective pain management – Targeting first clinical dose in calendar Q3 2023; Phase II top-line data within 12 months – Ended quarter with $42.4 million in cash and equivalents, providing over two years of runway TORONTO, CANADA — (February 15, … Continued
more
– Recent animal data on otenaproxesul’s new formulation confirm rapid drug uptake and potential for effective pain management – Targeting first clinical dose in calendar Q3 2023; Phase II top-line data within 12 months – Ended quarter with $42.4 million in cash and equivalents, providing over two years of runway TORONTO, CANADA — (February 15, … Continued